NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
about
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent CancersTargeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical ApproachesNeutrophils in Cancer: Two Sides of the Same Coin4-1BB agonism: adding the accelerator to cancer immunotherapyAntibody-Dependent Cell-Mediated Cytotoxicity Epitopes on the Hemagglutinin Head Region of Pandemic H1N1 Influenza Virus Play Detrimental Roles in H1N1-Infected MiceFCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceHLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyEnhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target AntigenKIR Genes and Their Ligands Predict the Response to Anti-EGFR Monoclonal Antibodies in Solid Tumors.In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer.Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.Cellular immunity augmentation in mainstream oncologic therapyThe Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments.A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.Innate immune mediators in cancer: between defense and resistance.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Resistance to immunotherapy: clouds in a bright sky.What Fuels Natural Killers? Metabolism and NK Cell ResponsesBiodegradable Viral Nanoparticle/Polymer Implants Prepared via Melt-Processing.CD70 turns on NK cells to attack lymphoma.Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of LiteratureA potent human neutralizing antibody Fc-dependently reduces established HBV infectionsNeuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.Phenotypic and Functional Characterization of Circulatory, Splenic, and Hepatic NK Cells in Simian Immunodeficiency Virus-Controlling Macaques.Natural Killer Cells - Their Role in Tumour ImmunosurveillanceReal-time Characterization of Antibody Binding to Receptors on Living Immune Cells.Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Leveraging natural killer cells for cancer immunotherapy.Dynamics of Sendai virus spread, clearance, and immunotherapeutic efficacy after hematopoietic cell transplant imaged non-invasively in mice.Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.Human Pluripotent Stem Cells to Produce Cell-based Cancer Immunotherapy.Systems serology: profiling vaccine induced humoral immunity against HIV.Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse.Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.Innate immune cells for immunotherapy of autoimmune and cancer disorders.Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering.
P2860
Q26751473-79B7A8AB-F5A7-4AC4-9E8B-730176F9BF15Q26752518-48B4CA7B-EA88-419E-8668-04A4D28F5859Q26773072-FCD2C0D6-8B94-4FB5-B098-C78910BB6AC4Q28079622-2FD0CD73-6AEB-4A5B-898F-BFDC9BEEF5FCQ30400732-B25C116C-3589-4FFC-A131-093400F5F36DQ33607015-75AF2169-2C0F-4C18-92C9-FDEB492A01E7Q33785744-1F5B33A2-4D41-4F65-9A52-4F8621CBA5F6Q36056627-15D7567C-9444-44F1-993D-048757D0F55BQ37471733-E8346D50-925E-4F8A-B204-37F909A1886FQ37625627-D617CFCC-7C4D-4CA2-B421-A9CEF54536E6Q37658381-1300364E-145F-4CDF-B702-8D55C3EFB245Q38557424-343566BD-95FB-442B-A628-55E822074FC1Q38670431-37312933-4CA0-46E8-91F4-E527DA68F7B9Q38744668-4DBF36E3-A710-413D-B734-04548C2030FEQ38920328-3C13B536-CEDB-44FC-B6E0-DAC5B50E05F5Q38991015-7EED2D87-03B8-4BC0-AE74-25CBB2C490E4Q39013616-F4D32A8C-10F2-459C-8EB4-583AE6663301Q39236810-C0BB701B-2F1A-4F87-9469-7310B39D44D5Q39249602-A58D3F5C-D14A-4382-90AA-ECD658B430D3Q40043641-B3E7EED4-AFBF-4111-B82D-A3A03B1C5A3CQ41080703-9150EA35-1CC7-423B-A19F-460736D12555Q41260777-8BF2616D-BB23-4B9A-AB64-8ED5B1B41F3FQ41619501-E4C2A0B4-10E3-47DC-9998-565C396846CCQ41671765-B8AF5DCC-2C64-4EE4-B9B6-184F2BC3B6B8Q41689901-754C4DFD-4164-4368-9D5A-16B4B40B998BQ41930380-D8F91A69-2738-4E23-BB9C-38A1E130B24DQ42282419-9DBBCFA0-3DC0-4202-B1CD-E64925578094Q42290751-B0CBE9F2-A774-4C61-810C-68CFBE47CFCDQ42660142-3F5DC426-F0E8-4C99-ADEF-686B711BEB28Q43865719-29C02392-EAD1-4FE1-A3B1-CB4B39E06BC2Q45325417-140B9FFA-DDDF-459F-86BF-064B77FA11DFQ46091824-95A29D89-4ED0-4306-9766-ED9CDCCF9754Q46350666-2DF9ED64-3BDE-42BC-8922-13A5AE923608Q47104983-CD712FB8-9FEA-40C7-86F1-55E0FB465CEDQ47132253-2332C6D5-14FF-458C-8A55-B209E9ECD1D4Q47156423-EEEEBD8D-BE96-451A-8397-A258CD350278Q47216941-0692A210-CF4B-401C-A03A-B43A0DADEA9DQ48316500-03F3F40B-E9E4-48AA-BC63-B31EA48814DDQ51760860-F2F73E80-8754-45E5-96C3-1A60D99EEFC7Q52615722-803CEF71-1DAF-4762-80F3-96D65633300A
P2860
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@ast
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@en
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@nl
type
label
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@ast
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@en
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@nl
prefLabel
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@ast
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@en
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@nl
P2093
P2860
P921
P3181
P356
P1476
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
@en
P2093
Amy K Erbe
Jacquelyn A Hank
Paul M Sondel
Zachary S Morris
P2860
P3181
P356
10.3389/FIMMU.2015.00368
P407
P577
2015-01-01T00:00:00Z